Show simple item record

dc.contributor.authorAbrahamsson, Johan
dc.contributor.authorAaltonen, Kristina
dc.contributor.authorEngilbertsson, Helgi
dc.contributor.authorLiedberg, Fredrik
dc.contributor.authorPatschan, Oliver
dc.contributor.authorRydén, Lisa
dc.contributor.authorSjödahl, Gottfrid
dc.contributor.authorGudjonsson, Sigurdur
dc.date.accessioned2017-12-21T15:13:56Z
dc.date.available2017-12-21T15:13:56Z
dc.date.issued2017-10
dc.date.submitted2017
dc.identifier.citationCirculating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. 2017, 35 (10):606.e9-606.e16 Urol. Oncol.en
dc.identifier.issn1873-2496
dc.identifier.pmid28676151
dc.identifier.doi10.1016/j.urolonc.2017.05.021
dc.identifier.urihttp://hdl.handle.net/2336/620416
dc.description.abstractThere are currently no methods in clinical use that can detect early systemic dissemination of urothelial tumor cells.
dc.description.abstractTo evaluate measurement of circulating tumor cells (CTCs) as a biomarker for disseminated disease in patients with advanced bladder cancer.
dc.description.abstractBetween March 2013 and October 2015, 88 patients were prospectively included in the study: 78 were scheduled for radical cystectomy (RC) ± perioperative chemotherapy and 10 treated with palliative chemotherapy. The CellSearch CTC test was further assessed in this context by investigating expression of epithelial cell adhesion molecule (EpCAM) in primary tumors obtained at cystectomy from an independent cohort of 409 patients.
dc.description.abstractPresence of CTCs was tested for association with tumor stage, lymph node metastases, metastatic disease on [18 F]-fluorodeoxyglucose-positron emission tomography (FDG-PET), and cancer-specific and progression-free survival.
dc.description.abstractCTCs were detected in 17/88 patients (19%). In 61 patients who underwent FDG-PET-computed tomography (CT), a statistically significant association with presence of CTCs was found for radiological metastatic disease but not for normal PET-CT results (12/35 [34%] vs. 2/26 [8%], P = 0.014). After a median follow-up time of 16.5 months (95% CI: 9.6-21.4), presence of CTCs was associated with an increased risk of progression among patients treated with RC with or without perioperative chemotherapy (n = 75, P = 0.049). A multivariate analysis adjusted for clinical tumor stage, clinical lymph node status, and age showed that CTCs were an independent marker of progression (n = 75; hazard ratio = 2.78; 95% CI: 1.005-7.69; P = 0.049) but not of cancer-specific death (P = 0.596). In 409 cystectomised patients, more than 392 (96%) of the bladder tumors expressed EpCAM.
dc.description.abstractCTCs were present in 19% of patients with advanced urothelial tumors and were associated with metastatic disease on FDG-PET-CT and with increased risk of disease progression after RC. A significant portion of urothelial cancer cells do express EpCAM and can thus be identified using EpCAM-antigen-based CTC detection methods.
dc.description.sponsorshipSwedish Cancer Society Hillevi Fries Research Fund Gosta Jonsson Research Fund Gunnar Nilsson Research Fund Wane University Hospital Research Funds Maud and Birger Gustaysson Research Fund Lund University Medical Faculty Foundation, Sweden (ALF)en
dc.language.isoenen
dc.publisherElsevier Scienceen
dc.relation.urlhttps://ac.els-cdn.com/S107814391730251X/1-s2.0-S107814391730251X-main.pdf?_tid=4ba8c886-e660-11e7-8525-00000aab0f6c&acdnat=1513868872_29961e7cc900e1dea92bc6a3a0e6403fen
dc.rightsArchived with thanks to Urologic oncologyen
dc.subjectKrabbameinen
dc.subjectÞvagblaðraen
dc.subjectURO12en
dc.subject.meshUrinary Bladder Neoplasmsen
dc.subject.meshNeoplastic Cells, Circulatingen
dc.titleCirculating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival.en
dc.typeArticleen
dc.contributor.department[ 1 ] Skane Univ Hosp, Dept Urol, Lund, Sweden Show more [ 2 ] Lund Univ, Dept Translat Med, Malmo, Sweden Show more [ 3 ] Lund Univ, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden Show more [ 4 ] Skane Univ Hosp, Dept Surg, Lund, Sweden Show more [ 5 ] Lund Univ, Div Surg, Dept Clin Sci, Lund, Sweden Show more [ 6 ] Landspitali Univ Hosp, Dept Urol, Reykjavik, Icelanden
dc.identifier.journalUrologic oncologyen
dc.rights.accessNational Consortium - Landsaðganguren
html.description.abstractThere are currently no methods in clinical use that can detect early systemic dissemination of urothelial tumor cells.
html.description.abstractTo evaluate measurement of circulating tumor cells (CTCs) as a biomarker for disseminated disease in patients with advanced bladder cancer.
html.description.abstractBetween March 2013 and October 2015, 88 patients were prospectively included in the study: 78 were scheduled for radical cystectomy (RC) ± perioperative chemotherapy and 10 treated with palliative chemotherapy. The CellSearch CTC test was further assessed in this context by investigating expression of epithelial cell adhesion molecule (EpCAM) in primary tumors obtained at cystectomy from an independent cohort of 409 patients.
html.description.abstractPresence of CTCs was tested for association with tumor stage, lymph node metastases, metastatic disease on [18 F]-fluorodeoxyglucose-positron emission tomography (FDG-PET), and cancer-specific and progression-free survival.
html.description.abstractCTCs were detected in 17/88 patients (19%). In 61 patients who underwent FDG-PET-computed tomography (CT), a statistically significant association with presence of CTCs was found for radiological metastatic disease but not for normal PET-CT results (12/35 [34%] vs. 2/26 [8%], P = 0.014). After a median follow-up time of 16.5 months (95% CI: 9.6-21.4), presence of CTCs was associated with an increased risk of progression among patients treated with RC with or without perioperative chemotherapy (n = 75, P = 0.049). A multivariate analysis adjusted for clinical tumor stage, clinical lymph node status, and age showed that CTCs were an independent marker of progression (n = 75; hazard ratio = 2.78; 95% CI: 1.005-7.69; P = 0.049) but not of cancer-specific death (P = 0.596). In 409 cystectomised patients, more than 392 (96%) of the bladder tumors expressed EpCAM.
html.description.abstractCTCs were present in 19% of patients with advanced urothelial tumors and were associated with metastatic disease on FDG-PET-CT and with increased risk of disease progression after RC. A significant portion of urothelial cancer cells do express EpCAM and can thus be identified using EpCAM-antigen-based CTC detection methods.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record